Bronchiectasis

1. W. P. Rivindu H. Wickramanayake
Group no. 04a
6th Year 2nd Semester – 2020 November
Tbilisi State Medical University, Georgia
Bronchiectasis

2. ● A chronic lung disease characterized by persistent and lifelong widening of
the bronchial airways and weakening of the function mucociliary transport
mechanism owing to repeated infection contributing to bacterial invasion and
mucus pooling throughout the bronchial tree.
● Is responsible for the significant loss of lung function and one that can result in
considerable morbidity and even early mortality.
● It can exist in any age group. However, it generally occurred in childhood
during the pre-antibiotic period.
● Recent evidence shows that bronchiectasis disproportionately affects women &
older individuals, and may be contributing to an increasing healthcare burden.
● Historically, the most common cause of bronchiectasis was thought to be an
antecedent respiratory infection, often during childhood. The causes are
idiopathic, acquired, or infection-related.

3. ● Bacterial Infections - a. Mycobacterium: Tuberculosis and atypical
b. Haemophilus influenzae
c. Pseudomonas aeruginosa
d. Staphylococcus aureus
e. Mycoplasma and HIV
● Viral Infections - Respiratory syncytial virus and measles
● Fungal Infections
● Bronchial obstruction - a. Foreign body
b. Mucus plug
c. Tumors
d. Hilar lymphadenopathy (right middle lobe
syndrome: extrinsic compression from postinfectious adenopathy)

4. ● Postinflammatory pneumonitis
a. Chronic aspiration/gastroesophageal reflux disorder
b. Chronic sinusitis
c. Inhalational injury
● Congenital/Genetic - a. Cystic fibrosis
b. Young syndrome
c. PCD: primary ciliary dyskinesia (Kartenger Syndrome)
d. Immunodeficiency (hypogammaglobulinemia)
e. Alpha1-antitrypsin deficiency (AAT)
f. Mounier-Kuhn syndrome
● Inflammatory diseases
a. Ulcerative colitis
b. Rheumatoid arthritis
c. Sjögren syndrome

5. ● Pulmonary Diseases
a. Asthma
b. Bronchomalacia
c. Cronic-obstructive pulmonary disease (COPD) (reported in up to
50% of patients with moderate-to-severe COPD)
d. Diffuse panbronchiolitis
e. Idiopathic pulmonary fibrosis (traction bronchiectasis)
● Altered immune response
a. Allergic Bronchopulmonary Aspergillosis
b. Hypersensitivity pneumonitis
● Others
- Yellow nail syndrome (yellow nails, lymphedema, pleural effusion,
bronchiectasis 40% first described in 1964)

6. Pathophysiology
● The pathogenesis of bronchiectasis are recurrent infections, airway
obstruction, and peri-bronchial fibrosis.
● Neutrophils dominate airway inflammation in bronchiectasis, driven by high
concentrations of neutrophil chemo-attractants such as interleukin-8 (CXCL-8),
and leukotriene B4.
● Airway bacterial colonization occurs because of impaired mucociliary
clearance and because of the failure of neutrophil opsono-phagocytic killing.
● Other mechanisms of immune dysfunction include the inability to clear
apoptotic cells and invasion of T-cells, with recent reports leading to Th17 cells
playing a significant role.
● Histologic changes in bronchiectasis include cartilage destruction and
fibrosis, mucosal and mucous gland hyperplasia, inflammatory cell
infiltration, and increased mucous and exudate.

7. ● History of a long-standing cough with purulence is typical of bronchiectasis.
● Repetitive pulmonary infections that require antibiotics over several years.
● Sputum is typically mucoid and relatively odorless
● Progressive dyspnea,
● Intermittent wheezing,
● The hemoptysis is mild and manifested by blood flecks in the patient's usual
purulent sputum, which is occasionally life-threatening.
● Often patients are diagnosed after many years of symptoms when a chronic
cough or hemoptysis becomes debilitating.
● Pleuritic chest pain (secondary to chronic coughing)
● And associated fatigue and weight loss.
● Physical findings are nonspecific.
History and Physical

8. ● General findings - Digital clubbing (2% to 3%), cyanosis, plethora, wasting,
and weight loss.
● Local chest examination: Most commonly crackles and wheezes on
auscultation.
- Crackles, usually bi-basal.
- Wheezing (wheezing may be due to airflow obstruction from secretions)
● Clinical Features of Associated Causative condition:
a. Connective tissue diseases: Arthritis Sicca syndrome
b. Allergic Bronchopulmonary Aspergillosis(ABPA): Prominent wheezing
c. Bronchial obstruction: localized wheezing
d. PCD, CF, Young Syndrome: Recurrent sinus disease, infertility
e. Features of acute exacerbation of bronchiectasis: Change in sputum
production, increased dyspnea, increased cough, fever, increased wheezing, and
reduced pulmonary function.

9. ● The British Thoracic Society (BTS) suggest checking for underlying factors
involving immunoglobulin tests (IgA, IgM, IgG, and IgE), and
● Testing to exclude ABPA (specific IgE to Aspergillus, IgG to Aspergillus,
and eosinophil count).
● Sputum culture to exclude nontuberculous mycobacteria (NTM) and
assessment of autoantibodies are also suggested.
● Testing for cystic fibrosis (CF) (sweat test and/or screening for common CF
mutations) is recommended for patients aged younger than 40 years or with
recurrent Pseudomonas aeruginosa and Staphylococcus aureus isolation, or
upper lobe predominant disease irrespective of age.
● Alpha-1 Antitrypsin level, Ciliary function analysis, and Serology for
HIV if indicated.
Evaluation

10. ● The initial study performed in suspected bronchiectasis.
● Signs - Parallel linear densities, tram-track opacities, or ring shadows
reflecting thickened and abnormally dilated bronchial walls.
● Signs of complications/exacerbations, such as patchy densities due to mucoid
impaction (mucus may become of high density due to chronic inspissation) and
consolidation, volume loss secondary to mucoid bronchial obstruction or chronic
cicatrization(Scar forming at the site of a healing wound) are also seen.
● In comparison to chest x-ray, CT is both more sensitive and provides more
specific information.
● In addition to making the diagnosis, the pattern of disease on HRCT may enable
one to limit the differential to a single/few specific causative entities.
Chest Radiography

11. ● The CT chest signs of bronchiectasis
- Bronchial dilation, the cardinal sign of bronchiectasis, is characterized:
- On HRCT by a broncho arterial ratio (BAR) of more than 1
- Lack of bronchial tapering (normal airways diminish in caliber as
they extend toward the lung periphery)
- Visibility of airways within 1 cm of the pleural surface (normal
airways should not be visualized this far out in the lung periphery) or abutting the
mediastinal pleural surface.
● Usual Pattern on High-Resolution CT scan Chest
1. Cylindrical (tram track sign): Dilated airways seen in a horizontal
orientation.
2. Signet-ring: The dilated airway lies adjacent to a pulmonary artery branch
giving the appearance of a ring (internal bronchial diameter greater than that of the
adjacent pulmonary artery).
Continued;

12. 3. Varicose: Implies non-uniform bronchial dilatation. The bronchi resemble
like varicose veins. The luminal dilatation is characterized by alternating areas of
luminal dilatation and constriction, creating a beaded appearance, and the wall
thickening is irregular. This varicose bronchiectasis serves as an intermediate step
before the development of grossly dilated cystic airways.
4. Cystic or saccular: A cluster of thin-walled cystic spaces.
Mosaic lung attenuation: The terminology is used to characterize heterogeneous
lung density in the damaged lung segments owing to air trapping and hence has a
geographic distribution. On expiration, this result can be produced or exaggerated.
5. Dilated bronchial arteries: These are best-demonstrated post
administration of intravenous contrast. These tortuous vessels extend along the
central airways toward the hila. It is these vessels that are often responsible for
hemoptysis.

13. Other Findings:
- Lobar collapse
- Mycetoma formation (Fungus ball):
- Aspergillus fumigatus (a fungus) may colonize
dilated airways or bullae/cavities. It is a major source of hemoptysis.
- Decreased Lung function:
- Airflow obstruction: FEV1 decreased
- Air trapping: Residual volume increased
Continued;
For further details, please refer : https://radiologykey.com/bronchiectasis-2/

14. ● Bronchiectasis is treatable but rarely curable.
● Treatment Goals:
1. Identifying and treating the underlying cause
2. Improve tracheobronchial clearance
3. Control infection
4. Reverse airflow obstruction
● General Management:
1. Identifying and treating the underlying cause: Immunoglobulin
replacement, steroids, and antifungals for ABPA, treatment for NTM, and of CF
all represent opportunities to treat the underlying cause specifically, and systematic
testing of all patients is recommended in consensus guidelines.
Treatment / Management

15. 2. Improve tracheobronchial clearance:
- Mucus clearance, the mainstay of therapy in bronchiectasis,
- Postural drainage consists of adopting a position in which the
uppermost lobe is drained, and
- should be performed for a minimum of 5 to 10 minutes twice a day.
Efficiently performed, this is of great value both in reducing the amount of
cough and sputum and in preventing recurrent episodes of bronchopulmonary
infection.
- Deep breathing followed by forced expiratory maneuvers (the
"active cycle of breathing" technique) is of help in allowing secretions in the
dilated bronchi to gravitate towards the trachea, from which vigorous coughing
can clear them.
- "Percussion" of the chest wall with cupped hands may help to
dislodge sputum, and a number of mechanical devices are available, which cause
the chest wall to oscillate, thus achieving the same effect.
Continued;

16. 3. Control infection:
- The choice of Abx. - based on the results of culture and sensitivity.
- When no specific pathogen is identified, and the patient is not
seriously ill, an oral agent like amoxicillin, co-amoxiclav, or macrolides for 2
weeks is sufficient.
- Use a higher dose of oral amoxicillin 1 gm twice per day for 2
weeks, especially if colonized with H. influenza.
- If pseudomonas-colonized, then a 2-week course of ciprofloxacin
750 mg twice per day (with cautious use in the elderly) is reasonable.
- For patients with moderate-to-severe symptoms, parenteral Abx.,
such as an aminoglycoside (gentamicin, tobramycin), and antipseudomonal synthetic
penicillin, a third-generation cephalosporin, or a fluoroquinolone, may be indicated.
- Treatment for Pseudomonas isolates 2 weeks of intravenous (IV)
antipseudomonal antibiotics, nebulized colistin for 3 months, or nebulized
colistin for 3 months with an additional 4 weeks of oral ciprofloxacin.

17. 4. Control reverse airflow obstruction:
- In patients with airflow obstruction, inhaled bronchodilators and
corticosteroids should be used to enhance airway patency.
5. Lifestyle modifications:
- As with other respiratory diseases, patients with bronchiectasis should
be encouraged to stop smoking.
- Vaccination against influenza and pneumococcal disease is also
recommended.
Continued;
- Maintenance therapy with intermittent antibiotics is not used routinely in
patients with non-CF bronchiectasis, and the decision to use long-term antibiotics
should be individualized.
- Inhaled aminoglycosides can be of benefit in chronic non-CF
bronchiectasis; however, the treatment needs to be of sustained duration.

18. Adjunctive Surgical Treatment:
● Only indicated in a small proportion of cases. These are usually
young patients in whom the bronchiectasis is unilateral and
confined to a single lobe or segment, as demonstrated by CT.
● On patients with advanced or complicated disease.
● Single- or double-lung transplantation has been used as a treatment
of severe bronchiectasis, predominantly when related to CF. In
general, consider patients with CF and bronchiectasis for lung
transplantation when FEV falls below 30% of the predicted value. Female
patients and younger patients may need to be considered sooner.
● Massive hemoptysis: Bronchial artery embolization and/or surgery
is first-line therapy for the management of massive hemoptysis.
Continued;

19. • Alpha 1 antitrypsin deficiency
• Aspiration pneumonitis and pneumonia
• Asthma
• Bronchitis
• Chronic obstructive pulmonary lung disease
• Cystic Fibrosis
• Emphysema
• Gastroesophageal reflux disease
• Tuberculosis
Differential Diagnosis

20. ● Bronchiectasis complications include;
- Pneumonia,
- Lung abscess,
- Empyema,
- Septicemia,
- Cor pulmonale,
- Respiratory failure,
- Recurrent pleurisy
- Secondary amyloidosis with nephrotic syndrome.
● Prognosis: The disease is progressive when associated with ciliary dysfunction
and cystic fibrosis, and eventually causes respiratory failure in other patients.
The prognosis can be relatively good if postural drainage is performed regularly,
and antibiotics are used judiciously.

21. References;
1. Harrison’s Principles of Internal Medicine, 19th Edition
2. https://www.ncbi.nlm.nih.gov/books/NBK430810/
3. Schoovaerts K, Lorent N, Goeminne P, Aliberti S, Dupont L. National Survey on the
Management of Adult Bronchiectasis in Belgium. COPD. 2019 Feb;16(1):72-74. [PubMed]
4. O'Neill K, O'Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary
rehabilitation in bronchiectasis. Respirology. 2019 Mar;24(3):227-237. [PubMed]
5. Bell SC, Elborn JS, Byrnes CA. Bronchiectasis: Treatment decisions for pulmonary
exacerbations and their prevention. Respirology. 2018 Nov;23(11):1006-1022. [PubMed]
6. Mitchelmore P, Wilson C, Hettle D. Risk of Bacterial Transmission in Bronchiectasis
Outpatient Clinics. Curr Pulmonol Rep. 2018;7(3):72-78. [PMC free article] [PubMed]
7. Dalrymple RA, Kenia P. European Respiratory Society guidelines for the diagnosis of primary
ciliary dyskinesia: a guideline review. Arch Dis Child Educ Pract Ed. 2019 Oct;104(5):265-
269. [PubMed]
8. Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg
M, Aliberti S, Chalmers JD. The overlap between bronchiectasis and chronic airway diseases:
state of the art and future directions. Eur Respir J. 2018 Sep;52(3) [PubMed]